Neurocrine Biosciences, Inc. (NBIX)
NASDAQ: NBIX · Real-Time Price · USD
157.21
-1.21 (-0.76%)
At close: May 18, 2026, 4:00 PM EDT
157.51
+0.30 (0.19%)
Pre-market: May 19, 2026, 6:52 AM EDT
Neurocrine Biosciences Stock Forecast
Stock Price Forecast
According to 27 analysts polled by S&P Global, Neurocrine Biosciences stock has a consensus rating of "Strong Buy" and an average price target of $190.99. The average 1-year stock price forecast is 21.49% higher than the current stock price, while the lowest is $144 (-8.40%) and the highest is $250.65 (+59.44%).
Price Target: $190.99 (+21.49%)
Analyst Consensus: Strong Buy
Analyst Ratings
The average analyst rating for Neurocrine Biosciences stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Dec '25 | Jan '26 | Feb '26 | Mar '26 | Apr '26 | May '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 12 | 12 | 11 | 11 | 11 | 10 |
| Buy | 8 | 6 | 8 | 8 | 9 | 8 |
| Hold | 2 | 3 | 3 | 3 | 3 | 3 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 22 | 21 | 22 | 22 | 23 | 21 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| JP Morgan | JP Morgan | Buy Maintains $177 → $185 | Buy | Maintains | $177 → $185 | +17.68% | May 8, 2026 |
| Truist Securities | Truist Securities | Strong Buy Maintains $140 → $155 | Strong Buy | Maintains | $140 → $155 | -1.41% | May 7, 2026 |
| Citigroup | Citigroup | Strong Buy Maintains $242 → $246 | Strong Buy | Maintains | $242 → $246 | +56.48% | May 6, 2026 |
| Morgan Stanley | Morgan Stanley | Hold Maintains $185 → $191 | Hold | Maintains | $185 → $191 | +21.49% | May 6, 2026 |
| RBC Capital | RBC Capital | Buy Maintains $176 → $180 | Buy | Maintains | $176 → $180 | +14.50% | May 6, 2026 |
Financial Forecast
Revenue This Year
3.58B
from 2.86B
Increased by 25.08%
Revenue Next Year
4.06B
from 3.58B
Increased by 13.56%
EPS This Year
6.07
from 4.67
Increased by 30.02%
EPS Next Year
8.30
from 6.07
Increased by 36.66%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 4.0B | 5.1B | ||||||
| Avg | 3.6B | 4.1B | ||||||
| Low | 3.3B | 3.4B |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 40.2% | 43.4% | ||||||
| Avg | 25.1% | 13.6% | ||||||
| Low | 16.0% | -5.1% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 7.46 | 12.23 | ||||||
| Avg | 6.07 | 8.30 | ||||||
| Low | 4.23 | 4.68 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 | 2031 | 2032 | 2033 |
|---|---|---|---|---|---|---|---|---|
| High | 59.6% | 101.5% | ||||||
| Avg | 30.0% | 36.7% | ||||||
| Low | -9.3% | -22.9% |
Sources: Price targets and consensus ratings provided by S&P Global Market Intelligence. Historical ratings and analyst data provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data sources.